IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?-Reference-Cited by-同舟云学术

IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?

Published:2019-02 Issue: Volume:38-39 Page:101604
ISSN:1521-6918
Container-title:Best Practice & Research Clinical Gastroenterology
language:en
Short-container-title:Best Practice & Research Clinical Gastroenterology

Author:

Ma Christopher^ORCID,Panaccione Remo,Khanna Reena,Feagan Brian G.,Jairath Vipul

Funder

Canadian Association of Gastroenterology

Canadian Institutes of Health Research

Publisher

Elsevier BV

Subject

Gastroenterology

Reference47 articles.

1. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease;Cohen;BMJ,2017

2. Loss of response to anti-TNFs: definition, epidemiology, and management;Roda;Clin Transl Gastroenterol,2016

3. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy;Danese;Aliment Pharmacol Ther,2011

4. Novel therapies and treatment strategies for patients with inflammatory bowel disease;Duijvestein;Curr Treat Options Gastroenterol,2018

5. Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease;Ma;Expert Opin Investig Drugs,2018

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Special Issue “Drug Treatments for Inflammatory Bowel Diseases”;Pharmaceuticals;2023-12-29

2. Morbus Crohn Update;Schweizer Gastroenterologie;2023-06-07

3. Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes;Drug Design, Development and Therapy;2023-01

4. Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing;Pharmaceuticals;2022-08-30

5. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study;Gastroenterology;2022-05